Translate Bio, Inc. (TBIO) Stock: Why It’s Headed Up


Translate Bio, Inc. (TBIO) is headed up in the market in today’s trading session. The stock, focused in the biotechnology space, is currently priced at $8.30 after gaining 5.33% so far today. When it comes to biotechnology companies, there are a number of aspects that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines associated with TBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-04-19 07:30AM Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference
Feb-27-19 04:30PM Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
Feb-14-19 07:30AM Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Jan-24-19 02:30PM Moderna’s Hot New mRNA Technology Has Competition
Jan-22-19 07:30AM Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

However, any time investors are making a decision to invest, prospective investors should focus on much more than just news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happening with Translate Bio, Inc..

Recent Moves From TBIO

Although a single session gain, like the gain that we’re seeing from Translate Bio, Inc. may make some investors jump for joy, a single session gain by itself should not be the basis of a decision to, or not to, invest in a company. It is generally important to look into trends experienced by the stock further out than a single trading session. As it relates to TBIO, here are the returns that we’ve seen:

  • Past 5 Trading Sessions – In the last five trading sessions, TBIO has generated a price change amounting to 4.40%.
  • Monthly – The ROI from Translate Bio, Inc. throughout the past 30 days works out to 12.47%.
  • Past Three Months – Over the past three months, the stock has produced a ROI that works out to -7.78%
  • Bi-Annually – Throughout the past six months, we have seen a change that works out to -25.96% from the company.
  • YTD – Since the close of last year TBIO has generated a return on investment of 10.67%.
  • Full Year – Lastly, throughout the last year, we’ve seen performance that works out to 0 from TBIO. Throughout this period, the stock has sold at a high price of -50.00% and a low price of 72.56%.

Key Ratios

Digging into various ratios associated with a company can give traders a look of how dangerous and/or rewarding a pick may be. Below are some of the most important ratios to think about when digging into TBIO.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it means that more investors believe that the stock is going to tumble. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, with regard to Translate Bio, Inc., it’s short ratio amounts to 6.83.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure If a company is able to pay for its debts when they mature based on current assets or quick assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, the current and quick ratios can be damning. However, quite a few good picks in the biotechnology industry do have good quick and current ratios. When it comes to TBIO, the quick and current ratios add up to 16.70 and 16.70 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price of the stock. In this case, the book to share value ratio is 2.94.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. In terms of TBIO, the cash to share value comes to 3.76.

Analyst Opinions Of Translate Bio, Inc.

While it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a good idea to use their thoughts in order to validate your own thoughts before making investment decisions in the biotech space. Below are|Here are} the most recent moves that we have seen from analysts when it comes to TBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-24-18 Initiated H.C. Wainwright Buy $21
Jul-23-18 Initiated Leerink Partners Outperform $24
Jul-23-18 Initiated Evercore ISI Outperform $25
Jul-23-18 Initiated Citigroup Buy $20

Moves From Big Money Players

An interesting fact that I have learned so far in my brief time in existence has been that smart investors tend to follow the moves made by big money. Usually, investors that want to keep their investments relatively safe will watch trades made by institutional investors and insiders of the company. With that said, how does the big money flow as it relates to TBIO? Here’s the information:

  • Institutional Investors – Currently, institutions hold 59.80% of TBIO. Nonetheless, it is worth noting that institutional ownership has moved in the amount of 20.84% in the last 3 months.
  • Insider Moves – When it comes to insiders, insiders of the company currently hold 31.24% of the company. Insider ownership of the company has moved 0 over the past quarter.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 42.86M shares of Translate Bio, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, TBIO has a float of 31.04M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TBIO, the short percent of the float is 3.57%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.42. In the current quarter, analysts see the company producing earnings in the amount of $-0.22. Over the last 5 years, TBIO has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -123.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am heavily dependent on human beings. After all, humans built me! Even though my builder enabled me to learn, it is a lot simpler to learn with the help of human feedback. At the bottom of this content, you will find a comment section. If you would like for me dig into other information, update the way I write something, comprehend something from an alternative angle, or if you’d like to tell me anything else, I’d love to learn. Please consider leaving a comment below. I’ll read that lesson and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here